Eisai, GSK Collaborates For Paritec In India
Eisai India and GlaxoSmithKline (GSK) have signed an agreement to co-promote Paritec (rabeprazole sodium) in India. Paritecis, developed by Eisai, is a proton pump inhibitor, approved for the treatment of acid-related disorders like peptic ulcer, reflux gastric disorders. Eisai is the first Japanese pharmaceutical major to enter India through a 100% subsidiary consequent to the enactment of Patent Act by the country.
S. Kalyanasundaram, Managing Director, GlaxoSmithKline, India and Vice President of South Asia GSK International, said: “We are pleased to enter into this co-promotion agreement with Eisai to facilitate the launch of Paritec in the Indian pharmaceutical market.”
GSK promotes a range of ethical formulations and is focussed in therapeutic areas of respiratory, dermatology and vaccines, besides having a presence in the areas of gastroenterology, dietary supplements, gynecology, neurology, cardiovascular and intensive care.
Eisai is a Japan-based company engaged in the discovery, development and marketing of pharmaceutical products for global usage.
Related Insight
Suppliers Directory
CellGenix Technologie Transfer - Ex Vivo Therapeutics, Cellular Therapeutics and Molecular Therapeutics
CellGenix Technologie Transfer GmbH is an innovative biopharmaceutical company headquartered in Freiburg, Germany.
Suppliers
Air Products - Worry-Free Gas Supply and Solutions
With a 99.95% on-time delivery record, excellent medical gas compliance and safety performance, and a total solutions approach to doing business, Air Products provides worry-free supply of nitrogen, hydrogen, oxygen, and other gases. We also provide technical support for a range of pharmaceutical and biological applications that include fermentation, hydrogenation, inerting and reaction cooling.
Suppliers
Eppendorf - Instruments and Systems for Cell Manipulation, Liquid Handling and DNA amplification
Eppendorf is a biotech company which develops, produces and distributes systems for use in life-science research laboratories worldwide.
Suppliers
Zenatek - Tracking, Monitoring and Reporting Systems for Goods in Transit
Zenatek is a Company with extensive management experience both in the civil and military logistical fields and in the development of software programming, in particular custom and commercial software. Zenatek was founded to supply services in ICT. It plans, realises and runs systems for dealing with and transmitting data and information on “computer” technology.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
OTC Intelligence
Using Technology to Deliver Complex Oncology Trials
Published by Medidata Solutions
White Papers
Biomarker Solutions
Published by Randox
White Papers
Comprehensive Feasibility Assessments in Eastern Europe - Luxury or Necessity?
Published by Centrical Global Limited
White Papers
Streamlining and Accelerating Change Control
Published by QUMAS
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.